PB60564USw

Abstract

The present invention relates to novel compounds of formula (I):



(I)

wherein

---- represents a single or a double bond;

R is a radical selected from:



in which R_1 is halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3;

R_2 is hydrogen or C_{1-4} alkyl;

R_3 is hydrogen, hydroxy or C_{1-4} alkyl;

R_4 is hydrogen or R_4 together with R_3 represents =O or =CH2;

R_5 is phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, C_{1-4} alkyl, hydroxy, cyano, C_{1-4} alkoxy, trifluoromethoxy, halogen or $S(O)qC_{1-4}$ alkyl;

R_6 and R_7 independently are hydrogen, cyano, C_{1-4} alkyl;

R_8 is $(CH_2)rR_{10}$;

R_9 is hydrogen, halogen, C_{3-7} cycloalkyl, hydroxy, nitro, cyano or C_{1-4} alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or C_{1-4} alkoxy;

R_{10} is hydrogen or C_{3-7} cycloalkyl;

n is 1 or 2;

q is 0, 1 or 2;

r is 0 or an integer from 1 to 4;

or a pharmaceutically acceptable salt or a solvate thereof, process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of the serotonin reuptake transporter protein.